Leerink Swann assumed coverage on shares of Cytokinetics (NASDAQ:CYTK) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm issued an outperform rating on the stock.
A number of other analysts have also recently weighed in on CYTK. Analysts at Canaccord Genuity reiterated a buy rating on shares of Cytokinetics in a research note to investors on Wednesday, June 26th. Separately, analysts at MLV Capital raised their price target on shares of Cytokinetics from $24.00 to $26.00 in a research note to investors on Wednesday, June 26th. They now have a buy rating on the stock. Finally, analysts at Needham & Company raised their price target on shares of Cytokinetics from $2.50 to $3.50 in a research note to investors on Thursday, June 13th. They now have a buy rating on the stock.
Eight investment analysts have rated the stock with a buy rating, Cytokinetics presently has a consensus rating of Buy and a consensus target price of $8.88.
Cytokinetics (NASDAQ: CYTK) traded up 0.45% on Wednesday, hitting $13.48. Cytokinetics has a 52-week low of $3.48 and a 52-week high of $14.28. The stock’s 50-day moving average is currently $10.75. The company’s market cap is $333.9 million.
Cytokinetics, Incorporated (NASDAQ: CYTK) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
